|
n (%)
|
---|
Benguela
|
Zaire
|
Lunda Sul
|
---|
DPb
|
ASAQa
|
ALa
|
ASAQa
|
ALa
|
DPb
|
---|
n = 85
|
n = 91
|
n = 94
|
n = 90
|
n = 91
|
n = 89
|
---|
Treatment failure
|
5 (6)
|
1 (1)
|
7 (7)
|
16 (18)
|
9 (10)
|
0
|
Early treatment failure
|
0
|
0
|
0
|
0
|
0
|
0
|
Late treatment failure
|
5 (6)
|
1 (1)
|
7 (7)
|
16 (18)
|
9 (10)
|
0
|
Recrudescence
|
0
|
0
|
4 (4)
|
5 (6)
|
3 (3)
|
0
|
Day 21
|
0
|
0
|
1 (1)
|
5 (6)
|
3 (3)
|
0
|
Day 28
|
0
|
0
|
3 (3)
|
0
|
0
|
0
|
Day 35
|
0
|
–
|
–
|
–
|
–
|
0
|
Day 42
|
0
|
–
|
–
|
–
|
–
|
0
|
Reinfection
|
5 (6)
|
1 (1)
|
3 (3)
|
11 (12)
|
6 (7)
|
0
|
Day 21
|
0
|
0
|
0
|
7 (8)
|
2 (2)
|
0
|
Day 28
|
0
|
1 (1)
|
3 (3)
|
4 (4)
|
4 (4)
|
0
|
Day 35
|
2 (2)
|
–
|
–
|
–
|
–
|
0
|
Day 42
|
3 (4)
|
–
|
–
|
–
|
–
|
0
|
Adequate clinical and parasitological response
|
80 (94)
|
90 (99)
|
87 (93)
|
74 (82)
|
82 (90)
|
89 (100)
|
- AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
- a28-day follow-up
- b42-day follow-up